BIOPHYTIS Aktie

>BIOPHYTIS Performance

1 Woche: 0%

1 Monat: -0,2%

3 Monate: -40,6%

6 Monate: -72,7%

1 Jahr: 0%

laufendes Jahr: -68,2%

>BIOPHYTIS Aktie

Name:

BIOPHYTIS NAM. EO -,10

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR001400OLP5 / A403QV

Symbol/ Ticker:

6XB3 (Frankfurt)

Kürzel:

FRA:6XB3, ETR:6XB3, 6XB3:GR

Index:

Webseite:

https://www.biophytis.com..

Marktkapitalisierung:

2.66 Mio. EUR

Umsatz:

EBITDA:

-11.8 Mio. EUR

Gewinn je Aktie:

-4.18 EUR

Schulden:

9.71 Mio. EUR

Liquide Mittel:

2.19 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 2.04 / -

Gewinnm./ Eigenkapitalr.:

- / -

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

BIOPHYTIS

Letzte Datenerhebung:

06.07.25

>BIOPHYTIS Eigentümer

Aktien: 20.15 Mio. St.

f.h. Aktien: 5.23 Mio. St.

Insider Eigner: 0.27%

Instit. Eigner: -

Leerverk. Aktien: -

>BIOPHYTIS Peer Group

ATON

BASTIDE LE CONFORT

DMS SA

GENOWAY

INTRASENSE

EUROMEDIS

LNA SANTE

ONCODESIGN

SAFE SA

VALBIOTIS

>BIOPHYTIS Chart & Kurs - Stuttgart

>BIOPHYTIS News

17.06.25 - 11:31	XFRA: 6XB3: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL BIOPHYTIS NAM. EO -,10 6XB3 FR001400OLP5 BAW/UFN...

17.06.25 - 11:31	XFRA: INSTRUMENT_SUSPENSION - EQUBF_01 (XETRA)
	Instrument ID [19470526] (6XB3 - FR001400OLP5) suspended...

22.04.25 - 07:06	Biophytis Targets Mobility Restoration in Patients with Obesity (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in dev......

09.04.25 - 07:42	Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 9, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the ......

24.03.25 - 07:48	Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity (Newsfile)
	96% of patients with obesity report experiencing muscle strength impairment, affecting their mobilityNew preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and ......

17.03.25 - 07:12	Biophytis Revolutionizes Sarcopenia (Newsfile)
	Publication of SARA-INT Phase II results for BIO101Confirmation of Phase 3 readinessParis, France and Cambridge, Massachusetts--(Newsfile Corp. - March 17, 2025) - Biophytis SA (FP: ALBPS) ("Bioph......

25.02.25 - 07:06	Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 25, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in t......

11.02.25 - 10:48	Biophytis unveils outlook strategies for 2025, to launch phase 3 of SARA clinical program (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.25 - 07:06	Biophytis Unveils Its Outlook Strategies for 2025 (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 11, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in ......

27.01.25 - 07:06	Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 27, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in t......

21.01.25 - 07:06	Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 21, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in t......

14.01.25 - 07:06	Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 14, 2025) - Biophytis SA (OTC Pink: BPTSY) (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company ......

09.01.25 - 11:33	XFRA : 6XB3: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIOPHYTIS NAM. EO -,80 6XB3 FR001400OLP5 AB/FROM ONWARDS 09.01.2025 11:28 CET...

06.01.25 - 14:33	XFRA : 6XB3: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL BIOPHYTIS NAM. EO -,80 6XB3 FR001400OLP5 BAW/UFN...

06.01.25 - 14:32	XFRA : INSTRUMENT_SUSPENSION - FR001400OLP5 (XETRA)
	Instrument ID [19470526] (6XB3 - FR001400OLP5) suspended...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Es geht nichts über ein ruhiges Leben, wie der Mann sagte, als er die Stelle eines Leuchtturmwärters annahm. - Charles Dickens

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram